AbbVie announced acquisition of psychedelic drug candidate bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion, strengthening AbbVie's growing neuroscience portfolio. The asset is in Phase II development for major depressive disorder. The deal follows an earlier collaboration and represents AbbVie's commitment to expanding in the emerging field of psychedelic therapeutics, capitalizing on promising early clinical results.